HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration

The continuously emerging SARS-CoV-2 variants pose a great challenge to the efficacy of current drugs, this necessitates the development of broad-spectrum antiviral drugs. In the previous study, we designed a recombinant protein, heptad repeat (HR) 121, as a variant-proof vaccine. Here, we found it...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ying, Shen, Fan, He, Wen-Qiang, Li, An-Qi, Li, Ming-Hua, Feng, Xiao-Li, Zheng, Yong-Tang, Pang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219671/
https://www.ncbi.nlm.nih.gov/pubmed/37360013
http://dx.doi.org/10.1016/j.apsb.2023.05.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219671/
https://www.ncbi.nlm.nih.gov/pubmed/37360013
http://dx.doi.org/10.1016/j.apsb.2023.05.030

Ejemplares similares